阅读说明：本技术 化合物 (Compound (I) ) 是由 S·科林伍德 C·麦卡锡 J·D·哈格雷夫 D·A·哈伊 T·B·斯科菲尔德 S·埃拉米 于 2019-01-25 设计创作，主要内容包括：通式(I)化合物：其中R<Sup>1</Sup>、R<Sup>2</Sup>、R<Sup>3</Sup>、R<Sup>4</Sup>、R<Sup>5a</Sup>、R<Sup>5b</Sup>、X<Sup>1</Sup>、X<Sup>2</Sup>、Z及Y如本文的定义,其为钙活化氯离子通道(calcium-activated chloride channel,CaCC)正向调节剂,TMEM16A。所述化合物可用于治疗受TMEM16A调节影响的疾病和病症,特别是呼吸系统疾病和病症。<Image he="389" wi="700" file="DDA0002603084150000011.GIF" imgContent="drawing" imgFormat="GIF" orientation="portrait" inline="no"></Image>(A compound of the general formula (I): wherein R is 1 、R 2 、R 3 、R 4 、R 5a 、R 5b 、X 1 、X 2 Z and Y are as defined herein, which are calcium-activated chloride channel (CaCC) positive regulators, TMEM 16A. The compounds are useful for the treatment of diseases and disorders which are affected by modulation of TMEM16A, particularly respiratory diseases and disorders.)